Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin

April 29, 2011 By Bio-Medicine.Org

HORSHAM, Pa., April 29, 2011 /PRNewswire/ — Centocor Ortho
Biotech Products, L.P., today announced that it has voluntarily
withdrawn the New Drug Application (NDA) for trabectedin for the
treatment of women with recurrent ovarian cancer (ROC).  The
withdrawal is based on the U.S. Food and Drug Administration’s
(FDA) recommendation that an additional Phase 3 study be conducted
to obtain approval.

The NDA was submitted to the FDA in November, 2008.  The
FDA issued a Complete Response letter in September 2009 and
requested additional information, including overall survival data
from the pivotal OVA-301 trial and additional clinical pharmacology
studies.  

The OVA-301 overall survival data will be the subject of a
poster presentation on June 5, 2011 at the Annual Meeting of the
American Society of Clinical Oncology (ASCO).

The company is evaluating the development program for YONDELIS
in recurrent ovarian cancer.

Ortho Biotech Oncology Research & Development, unit of
Johnson & Johnson Pharmaceutical Research & Development,
L.L.C., recently initiated a Phase 3 study (SAR-3007) with
trabectedin for metastatic L-sarcoma (liposarcoma or
leiomyosarcoma).

About Trabectedin

Trabectedin is a novel cytotoxic antitumor agent that was
originally derived from the marine tunicate, Ecteinascidia
turbinata
.  The compound is now produced synthetically.
 Trabectedin binds to the minor groove of DNA and bends it
toward the major groove, causing DNA adducts that interfere with
cell division and genetic transcription processes and DNA repair
machinery.  

Under a licensing agreement with PharmaMar SAU of Spain,
Centocor Ortho Biotech Products, L.P., has worldwide marketing
rights for trabectedin except in Europe, where the product is
marketed by PharmaMar SAU and Japan, where PharmaMar SAU and Taiho
Pharmaceutical CO., LTD. have a licensing agreement to develop and
commercial

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies
Biotronik
FDA approves Biotronik’s programmer for implanted cardiac rhythm management devices

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech